On December 30, 2025, Ultragenyx announced the completion of its rolling Biologics License Application (BLA) to the U.S. Food and Drug Administration for DTX401 (pariglasgene brecaparvovec), an AAV8 gene therapy targeting Glycogen Storage Disease Type Ia (GSDIa). The application package, now fully submitted with chemistry, manufacturing, and controls data, builds on Phase 3 GlucoGene trial results in 52 treated patients with up to six years of follow-up. Those results showed significant reductions in daily cornstarch intake, maintained low rates of hypoglycemia, improved fasting tolerance and meaningful quality-of-life gains on the Patient Global Impression of Change scale. The therapy retains Rare Pediatric Disease, orphan drug, Fast Track and RMAT designations from the FDA, and PRIME and orphan designations from the European Medicines Agency.

Following the BLA milestone, Ultragenyx shares jumped by 15.5% in the most recent trading session, driven by 11 million shares changing hands—nearly seven times the three-month daily average of 1.7 million. The volume spike signaled strong investor interest in the company’s lead pipeline asset and broader rare-disease portfolio. Market capitalization stands at approximately $1.9 billion, reflecting renewed optimism in Ultragenyx’s late-stage pipeline despite prior headwinds.

Despite two Phase 3 studies of setrusumab for osteogenesis imperfecta failing to meet primary endpoints, Wells Fargo analyst Benjamin Burnett kept an overweight rating on Ultragenyx and adjusted his price target down from $65 to $45, implying over 128% upside from the prior close. Burnett highlighted statistically significant bone mineral density gains in secondary analyses and awaits FDA feedback on both DTX401 and setrusumab data. He noted that Ultragenyx’s high gross margin of 79% and steady revenue streams from existing rare-disease products support a favorable risk-reward profile, even as the company continues to report net losses during its development phase.